Needle-Free COVID-19 vaccine shows promise in early trial
NCT ID NCT06851611
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed Phase 1 trial tested a nasal COVID-19 vaccine called COV2 in 40 healthy adults aged 18-75. The study compared two dose levels (low and high) and two administration methods (nasal drops vs. spray) to see which is safest and best at boosting immunity. Participants included both people who had prior COVID-19 vaccines and those who had never been vaccinated.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- COV2 nasal COVID-19 vaccine
- What this could lead to
- If successful, this could lead to a needle-free COVID-19 booster that is easier to administer and may better protect against variants.
- What could go wrong
- This is a small, early-phase trial focused on safety and immune response, not on preventing infection. The vaccine may not work as hoped in larger studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID19, SARS-COV-2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kuopio University Hospital
Kuopio, Northern Savonia, 70210, Finland